Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer’s dementia

BACKGROUND: Leukotriene receptor antagonists (LTRAs) alleviate Alzheimer’s disease (AD) pathology and improve cognition in animal models; however, clinical evidence is limited. This study aimed to explore the associations between the use of LTRAs (montelukast or zafirlukast) and cognitive performanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Lisa Y., Ouk, Michael, Wu, Che-Yuan, Rabin, Jennifer S., Lanctôt, Krista L., Herrmann, Nathan, Black, Sandra E., Edwards, Jodi D., Swardfager, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418104/
https://www.ncbi.nlm.nih.gov/pubmed/34479635
http://dx.doi.org/10.1186/s13195-021-00892-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418104/
https://www.ncbi.nlm.nih.gov/pubmed/34479635
http://dx.doi.org/10.1186/s13195-021-00892-7

Ejemplares similares